Jci_page_head_homepage_01 Jci_page_head_homepage_02
Laila D. McVay, Sue A. Keilbaugh, Tracie M.H. Wong, Sonja Kierstein, Marcus E. Shin, Michael Lehrke, Martina I. Lefterova, D. Edward Shifflett, Sean L. Barnes, Fabio Cominelli, Steven M. Cohn, Gail Hecht, Mitchell A. Lazar, Angela Haczku, Gary D. Wu
Published in Volume 116, Issue 11
J Clin Invest. 2006; 116(11):2914–2923 doi:10.1172/JCI28121
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Clinical evidence that RELMβ exacerbates DSS-induced colitis.

(A) Daily percent weight loss of wild-type and RELMβ–/– mice treated with 4% DSS (n = 8 per group; mean ± SEM; *P < 0.01). (B) Mean time (days) to onset of intestinal bleeding (hemoccult positivity) and loose stools in wild-type and RELMβ–/– mice treated with 4% DSS (n = 8 per group; mean ± SEM; #P < 0.05). (C) Percent survival of wild-type and RELMβ–/– mice treated with 4% DSS for 7 days (n = 8 per group). (D) Percentage of the colonic mucosa ulcerated in DSS-induced colitis in wild-type and RELMβ–/– mice treated with 4% DSS for 7 days (P < 0.05). (E) Quantification of TNF-α mRNA expression in the colon of wild-type and RELMβ–/– mice treated with 4% DSS for 7 days assessed by Northern blot normalized to 18S RNA (P < 0.05). (F) Percent survival of RELMβ–/– mice treated with 4% DSS that received enemas twice daily with either vehicle (PBS) or recombinant murine RELMβ (2 μg/ml) (n = 8 per group).